CD73-Positive Cell Spheroid Transplantation Attenuates Colonic Atrophy

Area of Science:

• Immunology
• Regenerative Medicine
• Gastroenterology

Background:

• Inflammatory bowel diseases (IBD) incidence is rising globally.
• Mesenchymal stem/stromal cells (MSCs) show therapeutic potential for IBD due to immunomodulatory properties.
• MSC heterogeneity complicates cell therapy efficacy for colitis, necessitating optimized cell selection and delivery.

Purpose of the Study:

• To determine the optimal method for mesenchymal stem/stromal cell (MSC) transplantation for colitis treatment.
• To investigate the therapeutic potential of CD73+ MSCs and their spheroid form delivered via the enteral route.
• To elucidate the mechanisms underlying MSC-mediated therapeutic effects in a colitis model.

Main Methods:

• Utilized CD73+ mesenchymal stem/stromal cells (MSCs) to obtain a homogeneous cell population.
• Employed mRNA sequencing to analyze gene expression profiles of CD73+ MSCs.
• Developed and tested three-dimensional (3D) CD73+ MSC spheroids for enteral delivery in a colitis model.

Main Results:

• CD73+ MSCs demonstrated downregulated inflammatory gene expression and upregulated extracellular matrix-related gene expression.
• Three-dimensional CD73+ MSC spheroids exhibited enhanced engraftment at injured intestinal sites via enteral delivery.
• Transplantation of CD73+ MSC spheroids facilitated extracellular matrix remodeling and reduced inflammatory gene expression in fibroblasts, attenuating colonic atrophy.

Conclusions:

• Homogeneous cell populations, like CD73+ MSCs, offer improved therapeutic benefits for inflammatory bowel disease (IBD) treatment.
• The interaction between intestinal fibroblasts and exogenous MSCs through tissue remodeling is a key mechanism for colitis prevention.
• Optimized MSC transplantation strategies, including cell selection (CD73+) and delivery (3D spheroids, enteral route), are crucial for effective colitis therapy.